Symbols / PLX
PLX Chart
About
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. It operates in the United States, Australia, Canada, Israel, Brazil, Russia, and Turkey. The company is headquartered in Hackensack. New Jersey.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 244.50M |
| Enterprise Value | 220.07M | Income | 5.39M | Sales | 61.84M |
| Book/sh | 0.66 | Cash/sh | 0.36 | Dividend Yield | — |
| Payout | 0.00% | Employees | 213 | IPO | — |
| P/E | 38.00 | Forward P/E | 4.90 | PEG | — |
| P/S | 3.95 | P/B | 4.61 | P/C | — |
| EV/EBITDA | 28.29 | EV/Sales | 3.56 | Quick Ratio | 2.00 |
| Current Ratio | 3.03 | Debt/Eq | 15.46 | LT Debt/Eq | — |
| EPS (ttm) | 0.08 | EPS next Y | 0.62 | EPS Growth | -1.00% |
| Revenue Growth | -0.60% | Earnings | 2026-03-17 | ROA | 5.53% |
| ROE | 12.64% | ROIC | — | Gross Margin | 57.54% |
| Oper. Margin | 11.94% | Profit Margin | 8.72% | Shs Outstand | 80.42M |
| Shs Float | 71.93M | Short Float | 5.34% | Short Ratio | 4.42 |
| Short Interest | — | 52W High | 3.17 | 52W Low | 1.32 |
| Beta | -0.22 | Avg Volume | 1.02M | Volume | 147.47K |
| Target Price | $11.00 | Recom | None | Prev Close | $3.01 |
| Price | $3.04 | Change | 1.00% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$11.00
Mean price target
2. Current target
$3.04
Latest analyst target
3. DCF / Fair value
$-3.00
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.04
Low
$10.00
High
$12.00
Mean
$11.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-11-21 | main | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-02-03 | main | HC Wainwright & Co. | Buy → Buy | $15 |
| 2023-11-14 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2023-10-31 | main | HC Wainwright & Co. | Buy → Buy | $10 |
News
RSS: Latest PLX news- A March Decision That Could Change Protalix BioTherapeutics Outlook - Seeking Alpha Sun, 01 Feb 2026 08
- Protalix BioTherapeutics, Inc. (PLX) Gains Investor Confidence With Major Stake Increase - Yahoo Finance Mon, 29 Sep 2025 07
- $PLX stock is up 13% today. Here's what we see in our data. - Quiver Quantitative Fri, 30 Jan 2026 08
- PLX Shares Jump 13% On EMA Committee’s Turnaround On New Dosing Regimen For Fabry Disease Therapy - Stocktwits Fri, 30 Jan 2026 22
- Brain tumor director and biotech CEO join Polaryx board as drug enters Phase 2 - Stock Titan hu, 05 Feb 2026 08
- Why Is Protalix BioTherapeutics Stock Falling On Friday? - Benzinga Fri, 17 Oct 2025 07
- How Could EMA's Elfabrio Decision Reshape Protalix BioTherapeutics' (PLX) Rare Disease Strategy? - simplywall.st Mon, 20 Oct 2025 07
- Protalix BioTherapeutics (PLX): Evaluating Valuation After EMA Setback on Elfabrio Dosing Regimen - Yahoo Finance Sat, 18 Oct 2025 07
- Earnings call transcript: Protalix Q1 2025 results miss forecasts, stock plunges - Investing.com Fri, 09 May 2025 07
- Protalix Wins EMA Panel Backing for New Elfabrio Dosing - TipRanks Fri, 30 Jan 2026 08
- Protalix BioTherapeutics Stock Tumbled 28% Today: Why The Latest CHMP Opinion Is Sparking Concerns Among Investors? - Stocktwits Fri, 17 Oct 2025 11
- Protalix rises as EU backs new dosing for Elfabrio (PLX:NYSE) - Seeking Alpha Fri, 30 Jan 2026 08
- Protalix BioTherapeutics (PLX) Valuation in Focus After EMA Setback on Elfabrio Dosing Schedule - simplywall.st Sat, 18 Oct 2025 07
- Exclusive Access: Protalix BioTherapeutics Reveals Growth Strategy at Premium Investor Summit - Stock Titan Mon, 24 Mar 2025 07
- Protalix Highlights Positive EMA Opinion on Elfabrio Dosing - TipRanks Wed, 11 Feb 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 56000 | 101360 | — | Purchase at price 1.81 per share. | BASHAN DROR | Chief Executive Officer | — | 2025-12-19 00:00:00 | D |
| 1 | 168 | 314 | — | Sale at price 1.87 per share. | BAR SHALEV AMOS | Director | — | 2025-11-18 00:00:00 | D |
| 2 | 7500 | — | — | Stock Award(Grant) at price 0.00 per share. | MELINCOFF GWEN A | Director | — | 2025-09-03 00:00:00 | I |
| 3 | 7500 | — | — | Stock Award(Grant) at price 0.00 per share. | BAR SHALEV AMOS | Director | — | 2025-09-03 00:00:00 | I |
| 4 | 7500 | — | — | Stock Award(Grant) at price 0.00 per share. | BOUDES POL F | Director | — | 2025-09-03 00:00:00 | I |
| 5 | 7500 | — | — | Stock Award(Grant) at price 0.00 per share. | SCHWARTZ AHARON | Director | — | 2025-09-03 00:00:00 | I |
| 6 | 25000 | — | — | Stock Award(Grant) at price 0.00 per share. | NAOS YARON | Officer | — | 2025-09-03 00:00:00 | I |
| 7 | 195000 | — | — | Stock Award(Grant) at price 0.00 per share. | BASHAN DROR | Chief Executive Officer | — | 2025-09-03 00:00:00 | I |
| 8 | 7500 | — | — | Stock Award(Grant) at price 0.00 per share. | FORSTER ELIOT | Director | — | 2025-09-03 00:00:00 | I |
| 9 | 7500 | — | — | Stock Award(Grant) at price 0.00 per share. | BEN ZVI SHMUEL | Director | — | 2025-09-03 00:00:00 | I |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.29 | 0.03 | 0.04 | 0.00 |
| NormalizedEBITDA | 6.52M | 12.94M | -10.78M | -18.94M |
| NetIncomeFromContinuingOperationNetMinorityInterest | 2.93M | 8.31M | -14.93M | -27.58M |
| ReconciledDepreciation | 1.30M | 1.19M | 1.09M | 1.12M |
| ReconciledCostOfRevenue | 24.32M | 22.98M | 19.59M | 16.35M |
| EBITDA | 6.52M | 12.94M | -10.78M | -18.94M |
| EBIT | 5.22M | 11.75M | -11.87M | -20.06M |
| NetInterestIncome | 237.00K | -1.89M | -1.38M | -7.12M |
| InterestExpense | 1.06M | 3.18M | 2.53M | 7.52M |
| InterestIncome | 1.30M | 1.29M | 1.15M | 401.00K |
| NormalizedIncome | 2.93M | 8.31M | -14.93M | -27.58M |
| NetIncomeFromContinuingAndDiscontinuedOperation | 2.93M | 8.31M | -14.93M | -27.58M |
| TotalExpenses | 49.48M | 55.03M | 60.65M | 58.81M |
| TotalOperatingIncomeAsReported | 3.92M | 10.46M | -13.01M | -20.46M |
| DilutedAverageShares | 81.06M | 82.42M | 48.47M | 44.14M |
| BasicAverageShares | 72.53M | 67.51M | 48.47M | 44.14M |
| DilutedEPS | 0.04 | 0.09 | -0.31 | -0.62 |
| BasicEPS | 0.04 | 0.12 | -0.31 | -0.62 |
| DilutedNIAvailtoComStockholders | 2.93M | 8.31M | -14.93M | -27.58M |
| NetIncomeCommonStockholders | 2.93M | 8.31M | -14.93M | -27.58M |
| NetIncome | 2.93M | 8.31M | -14.93M | -27.58M |
| NetIncomeIncludingNoncontrollingInterests | 2.93M | 8.31M | -14.93M | -27.58M |
| NetIncomeContinuousOperations | 2.93M | 8.31M | -14.93M | -27.58M |
| TaxProvision | 1.22M | 254.00K | 530.00K | 0.00 |
| PretaxIncome | 4.15M | 8.57M | -14.40M | -27.58M |
| NetNonOperatingInterestIncomeExpense | 237.00K | -1.89M | -1.38M | -7.12M |
| InterestExpenseNonOperating | 1.06M | 3.18M | 2.53M | 7.52M |
| InterestIncomeNonOperating | 1.30M | 1.29M | 1.15M | 401.00K |
| OperatingIncome | 3.92M | 10.46M | -13.01M | -20.46M |
| OperatingExpense | 25.16M | 32.05M | 41.06M | 42.46M |
| ResearchAndDevelopment | 12.97M | 17.09M | 29.35M | 29.73M |
| SellingGeneralAndAdministration | 12.19M | 14.96M | 11.71M | 12.73M |
| GrossProfit | 29.08M | 42.51M | 28.05M | 22.00M |
| CostOfRevenue | 24.32M | 22.98M | 19.59M | 16.35M |
| TotalRevenue | 53.40M | 65.49M | 47.64M | 38.35M |
| OperatingRevenue | 53.40M | 65.49M | 47.64M | 38.35M |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 75.85M | 72.95M | 53.79M | 45.56M |
| ShareIssued | 75.85M | 72.95M | 53.79M | 45.56M |
| NetDebt | 11.08M | |||
| TotalDebt | 5.53M | 26.28M | 33.47M | 33.47M |
| TangibleBookValue | 43.21M | 33.57M | -10.64M | -6.04M |
| InvestedCapital | 43.21M | 53.82M | 17.55M | 21.85M |
| WorkingCapital | 34.46M | 24.40M | 12.45M | 28.49M |
| NetTangibleAssets | 43.21M | 33.57M | -10.64M | -6.04M |
| CapitalLeaseObligations | 5.53M | 6.03M | 5.29M | 5.58M |
| CommonStockEquity | 43.21M | 33.57M | -10.64M | -6.04M |
| TotalCapitalization | 43.21M | 33.57M | 17.55M | 21.85M |
| TotalEquityGrossMinorityInterest | 43.21M | 33.57M | -10.64M | -6.04M |
| StockholdersEquity | 43.21M | 33.57M | -10.64M | -6.04M |
| RetainedEarnings | -378.39M | -381.55M | -389.86M | -374.93M |
| AdditionalPaidInCapital | 421.53M | 415.05M | 379.17M | 368.85M |
| CapitalStock | 76.00K | 73.00K | 54.00K | 46.00K |
| CommonStock | 76.00K | 73.00K | 54.00K | 46.00K |
| TotalLiabilitiesNetMinorityInterest | 30.21M | 50.87M | 66.43M | 79.70M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 4.58M | 5.33M | 34.00M | 46.52M |
| EmployeeBenefits | 559.00K | 714.00K | 1.64M | 2.47M |
| NonCurrentPensionAndOtherPostretirementBenefitPlans | 559.00K | 714.00K | 1.64M | 2.47M |
| NonCurrentDeferredLiabilities | 0.00 | 11.79M | ||
| NonCurrentDeferredRevenue | 0.00 | 11.79M | ||
| LongTermDebtAndCapitalLeaseObligation | 4.03M | 4.62M | 32.36M | 32.26M |
| LongTermCapitalLeaseObligation | 4.03M | 4.62M | 4.17M | 4.38M |
| LongTermDebt | 28.19M | 27.89M | ||
| CurrentLiabilities | 25.62M | 45.53M | 32.43M | 33.18M |
| CurrentDeferredLiabilities | 0.00 | 13.18M | 8.55M | |
| CurrentDeferredRevenue | 0.00 | 13.18M | 8.55M | |
| CurrentDebtAndCapitalLeaseObligation | 1.50M | 21.66M | 1.12M | 1.21M |
| CurrentCapitalLeaseObligation | 1.50M | 1.41M | 1.12M | 1.21M |
| CurrentDebt | 20.25M | |||
| OtherCurrentBorrowings | 20.25M | |||
| CurrentNotesPayable | 0.00 | |||
| PensionandOtherPostRetirementBenefitPlansCurrent | 1.81M | 1.60M | 1.40M | 1.51M |
| CurrentProvisions | 1.40M | 1.51M | ||
| PayablesAndAccruedExpenses | 22.31M | 22.27M | 16.73M | 21.91M |
| CurrentAccruedExpenses | 11.16M | 14.43M | 9.56M | 14.40M |
| InterestPayable | 0.00 | 511.00K | 719.00K | 767.00K |
| Payables | 11.14M | 7.83M | 7.17M | 7.51M |
| OtherPayable | 3.14M | 637.00K | 781.00K | 522.00K |
| TotalTaxPayable | 3.48M | 2.88M | 530.00K | |
| IncomeTaxPayable | 3.48M | 2.88M | 530.00K | |
| AccountsPayable | 4.53M | 4.32M | 5.86M | 6.99M |
| TotalAssets | 73.42M | 84.43M | 55.79M | 73.67M |
| TotalNonCurrentAssets | 13.34M | 14.50M | 10.91M | 12.00M |
| DefinedPensionBenefit | 462.00K | 528.00K | 1.27M | 2.08M |
| NonCurrentDeferredAssets | 2.86M | 3.09M | 0.00 | |
| NonCurrentDeferredTaxesAssets | 2.86M | 3.09M | 0.00 | |
| NetPPE | 10.02M | 10.88M | 9.64M | 9.92M |
| AccumulatedDepreciation | -35.74M | -34.69M | -33.69M | -32.75M |
| GrossPPE | 45.76M | 45.57M | 43.33M | 42.67M |
| Leases | 17.91M | 17.64M | 16.92M | 16.76M |
| OtherProperties | 24.47M | 24.84M | 23.58M | 23.20M |
| MachineryFurnitureEquipment | 3.37M | 3.08M | 2.82M | 2.72M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 60.08M | 69.93M | 44.88M | 61.67M |
| OtherCurrentAssets | 596.00K | 611.00K | 536.00K | 380.00K |
| RestrictedCash | 0.00 | |||
| PrepaidAssets | 500.00K | 444.00K | 774.00K | 905.00K |
| Inventory | 21.24M | 19.05M | 16.80M | 17.95M |
| FinishedGoods | 5.45M | 5.81M | 10.62M | 11.53M |
| WorkInProcess | 11.24M | 9.05M | 2.68M | 3.26M |
| RawMaterials | 4.55M | 4.18M | 3.51M | 3.17M |
| Receivables | 2.91M | 5.27M | 4.59M | 3.44M |
| AccountsReceivable | 2.91M | 5.27M | 4.59M | 3.44M |
| CashCashEquivalentsAndShortTermInvestments | 34.83M | 44.56M | 22.18M | 38.98M |
| OtherShortTermInvestments | 15.07M | 20.93M | 5.07M | 0.00 |
| CashAndCashEquivalents | 19.76M | 23.63M | 17.11M | 38.98M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | 7.39M | -2.47M | -25.63M | -11.74M |
| RepaymentOfDebt | -20.42M | 0.00 | 0.00 | -34.12M |
| IssuanceOfCapitalStock | 3.63M | 23.95M | 8.24M | 46.20M |
| CapitalExpenditure | -1.28M | -1.15M | -628.00K | -1.46M |
| InterestPaidSupplementalData | 3.41M | |||
| EndCashPosition | 19.76M | 23.63M | 17.11M | 38.98M |
| BeginningCashPosition | 23.63M | 17.11M | 38.98M | 18.27M |
| EffectOfExchangeRateChanges | 25.00K | -114.00K | -77.00K | 6.00K |
| ChangesInCash | -3.90M | 6.64M | -21.80M | 20.71M |
| FinancingCashFlow | -16.79M | 24.67M | 8.24M | 12.08M |
| CashFlowFromContinuingFinancingActivities | -16.79M | 24.67M | 8.24M | 12.08M |
| ProceedsFromStockOptionExercised | 0.00 | 712.00K | 2.00K | 0.00 |
| NetCommonStockIssuance | 3.63M | 23.95M | 8.24M | 46.20M |
| CommonStockIssuance | 3.63M | 23.95M | 8.24M | 46.20M |
| NetIssuancePaymentsOfDebt | -20.42M | 0.00 | 0.00 | -34.12M |
| NetShortTermDebtIssuance | -20.42M | 0.00 | 0.00 | |
| ShortTermDebtPayments | -20.42M | 0.00 | 0.00 | |
| NetLongTermDebtIssuance | 0.00 | 0.00 | -34.12M | |
| LongTermDebtPayments | 0.00 | 0.00 | -34.12M | |
| InvestingCashFlow | 4.22M | -16.71M | -5.04M | 18.92M |
| CashFlowFromContinuingInvestingActivities | 4.22M | -16.71M | -5.04M | 18.92M |
| NetOtherInvestingChanges | 80.00K | -142.00K | 593.00K | 327.00K |
| NetInvestmentPurchaseAndSale | 5.42M | -15.42M | -5.00M | 20.00M |
| SaleOfInvestment | 20.42M | 5.00M | 11.00M | 57.84M |
| PurchaseOfInvestment | -15.00M | -20.42M | -16.00M | -37.84M |
| NetPPEPurchaseAndSale | -1.28M | -1.15M | -628.00K | -1.41M |
| SaleOfPPE | 3.00K | 0.00 | 0.00 | 53.00K |
| PurchaseOfPPE | -1.28M | -1.15M | -628.00K | -1.46M |
| OperatingCashFlow | 8.67M | -1.32M | -25.00M | -10.29M |
| CashFlowFromContinuingOperatingActivities | 8.67M | -1.32M | -25.00M | -10.29M |
| ChangeInWorkingCapital | 811.00K | -10.54M | -12.02M | 9.90M |
| ChangeInOtherWorkingCapital | -13.18M | -7.16M | 13.23M | |
| ChangeInOtherCurrentLiabilities | 0.00 | 0.00 | -51.00K | |
| ChangeInOtherCurrentAssets | -4.00K | 13.00K | -5.00K | 241.00K |
| ChangeInPayablesAndAccruedExpense | 696.00K | 5.29M | -4.80M | 2.38M |
| ChangeInInventory | -2.20M | -2.24M | 1.15M | -4.87M |
| ChangeInReceivables | 2.32M | -428.00K | -1.19M | -1.03M |
| ChangesInAccountReceivables | 2.32M | -428.00K | -1.19M | -1.03M |
| OtherNonCashItems | 310.00K | -600.00K | -689.00K | 3.09M |
| StockBasedCompensation | 3.25M | 3.45M | 2.08M | 2.38M |
| DeferredTax | 236.00K | -3.09M | 0.00 | 0.00 |
| DeferredIncomeTax | 236.00K | -3.09M | 0.00 | 0.00 |
| DepreciationAmortizationDepletion | 1.30M | 1.19M | 1.09M | 1.12M |
| DepreciationAndAmortization | 1.30M | 1.19M | 1.09M | 1.12M |
| Depreciation | 1.30M | 1.19M | 1.09M | 1.12M |
| OperatingGainsLosses | -172.00K | -38.00K | -540.00K | 813.00K |
| PensionAndEmployeeBenefitExpense | -169.00K | -47.00K | -540.00K | 33.00K |
| GainLossOnSaleOfPPE | -3.00K | 9.00K | 0.00 | -51.00K |
| NetIncomeFromContinuingOperations | 2.93M | 8.31M | -14.93M | -27.58M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for PLX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|